Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baum

Showing results (381-390 of 398) with videos related to

Pageof 40
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Oncology Research and Treatment|May 24, 2014
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, GermanyDieter Hörsch, Kurt W Schmid, Martin Anlauf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
The Lancet. Oncology|May 31, 2024
Recent advances and impending challenges for the radiopharmaceutical sciences in oncologySuzanne E Lapi, Peter J H Scott, Andrew M Scott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsKambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, et al.
Der Pathologe|May 20, 2015
[Neuroendocrine neoplasms of the breast]M Anlauf, M Neumann, S Bomberg, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
Pageof 40

Showing results (381-390 of 398) with videos related to

Sort By:
Pageof 40
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.
Nuklearmedizin. Nuclear Medicine|March 15, 2018
[Somatostatin receptor PET/CT (SSTR-PET/CT)]C Boy, T Poeppel, J Kotzerke, et al.
Oncology Research and Treatment|May 24, 2014
Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, GermanyDieter Hörsch, Kurt W Schmid, Martin Anlauf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2020
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [<sup>177</sup>Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, et al.
The Lancet. Oncology|May 31, 2024
Recent advances and impending challenges for the radiopharmaceutical sciences in oncologySuzanne E Lapi, Peter J H Scott, Andrew M Scott, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 22, 2016
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer PatientsKambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, et al.
Der Pathologe|May 20, 2015
[Neuroendocrine neoplasms of the breast]M Anlauf, M Neumann, S Bomberg, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
Lancet (London, England)|July 2, 2026
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 29, 2023
Joint EANM/SNMMI procedure guideline for the use of <sup>177</sup>Lu-labeled PSMA-targeted radioligand-therapy (<sup>177</sup>Lu-PSMA-RLT)Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, et al.
Pageof 40